Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Feb 25

PMID 35203604

Authors

Yuan-Hong Jiang

Jia-Fong Jhang

Yu-Khun Lee

Hann-Chorng Kuo

Affiliations

Soon will be listed here.

Abstract

Low-energy shock wave (LESW) therapy is known to facilitate tissue regeneration with analgesic and anti-inflammatory effects. LESW treatment has been demonstrated to be effective in treating chronic prostatitis and pelvic pain syndrome as well as overactive bladder, and it has a potential effect on interstitial cystitis/bladder pain syndrome (IC/BPS) in humans. LESW reduces pain behavior, downregulates nerve growth factor expression, and suppresses bladder overactivity by decreasing the expression of inflammatory proteins. Previous rat IC models have shown that LESW can increase urothelial permeability, facilitate intravesical delivery of botulinum toxin A (BoNT-A), and block acetic acid-induced hyperactive bladder, suggesting that LESW might be a potential therapeutic module for relieving bladder inflammatory conditions, such as bladder oversensitivity, IC/BPS, and overactive bladder. A recent clinical trial showed that LESW monotherapy was associated with a significant reduction in pain scores and IC symptoms. BoNT-A detrusor injection or liposome-encapsulated BoNT-A instillation could also inhibit inflammation and improve IC symptoms. However, BoNT-A injection requires anesthesia and certain complications might occur. Our preliminary study using LESW plus intravesical BoNT-A instillation every week demonstrated an improvement in global response assessment without any adverse events. Moreover, an immunohistochemistry study revealed the presence of cleaved SNAP25 protein in the suburothelium of IC bladder tissue, indicating that BoNT-A could penetrate across the urothelial barrier after application of LESW. These results provide evidence for the efficacy and safety of this novel IC/BPS treatment by LESW plus BoNT-A instillation, without anesthesia, and no bladder injection. This article reviews the current evidence on LESW and LESW plus intravesical therapeutic agents on bladder disorders and the pathophysiology and pharmacological mechanism of this novel, minimally invasive treatment model for IC/BPS.

Citing Articles

Antinociceptive properties of intravesical/needle-free administration of abobotulinumtoxinA in a rodent model of chronic visceral pain: in vivo and histological evidence.

Auge C, Vogt M, Martin V, Lezmi S, Game X, Lluel P J Neural Transm (Vienna). 2025; .

PMID: 40089646 DOI: 10.1007/s00702-025-02906-2.

Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome.

Hu J, Tzeng H, Lee W, Li J, Chuang Y Int J Mol Sci. 2024; 25(15).

PMID: 39125584 PMC: 11312208. DOI: 10.3390/ijms25158015.

Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome.

Yu W, Jhang J, Kuo H Toxins (Basel). 2024; 16(2).

PMID: 38393152 PMC: 10891743. DOI: 10.3390/toxins16020074.

Mechanisms of oxidative stress in interstitial cystitis/bladder pain syndrome.

Mohammad A, Laboulaye M, Shenhar C, Dobberfuhl A Nat Rev Urol. 2024; 21(7):433-449.

PMID: 38326514 DOI: 10.1038/s41585-023-00850-y.

Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.

Marchenko I, Trushina D Pharmaceutics. 2023; 15(12).

PMID: 38140065 PMC: 10747982. DOI: 10.3390/pharmaceutics15122724.

References

Yu W, Jhang J, Ho H, Jiang Y, Lee C, Hsu Y . Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment. Sci Rep. 2021; 11(1):455. PMC: 7801576. DOI: 10.1038/s41598-020-80252-x. View

Cervigni M . Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2016; 4(6):638-42. PMC: 4708541. DOI: 10.3978/j.issn.2223-4683.2015.11.04. View

Iguchi N, Hou A, Koul H, Wilcox D . Partial bladder outlet obstruction in mice may cause E-cadherin repression through hypoxia induced pathway. J Urol. 2014; 192(3):964-72. DOI: 10.1016/j.juro.2014.03.037. View

Kuo H . Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int. 2005; 75(2):170-4. DOI: 10.1159/000087173. View

Warren J . Bladder pain syndrome/interstitial cystitis as a functional somatic syndrome. J Psychosom Res. 2014; 77(6):510-5. DOI: 10.1016/j.jpsychores.2014.10.003. View

Datey A, Chakravortty D, Gopalan J . An overview of a novel use of shockwaves to alter cell permeability: Comment on "Shock wave-induced permeabilization of mammalian cells" by Luz M. López-Marín et al. Phys Life Rev. 2018; 26-27:51-52. DOI: 10.1016/j.plrev.2018.06.018. View

Nageib M, Zahran M, El-Hefnawy A, Barakat N, Awadalla A, Aamer H . Low energy shock wave-delivered intravesical botulinum neurotoxin-A potentiates antioxidant genes and inhibits proinflammatory cytokines in rat model of overactive bladder. Neurourol Urodyn. 2020; 39(8):2447-2454. DOI: 10.1002/nau.24511. View

Lee Y, Jhang J, Jiang Y, Hsu Y, Ho H, Kuo H . Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics. Sci Rep. 2021; 11(1):17258. PMC: 8390653. DOI: 10.1038/s41598-021-96810-w. View

Jhang J, Jiang Y, Hsu Y, Ho H, Birder L, Lin T . Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection. Int Neurourol J. 2022; 26(Suppl 1):S57-67. PMC: 8896774. DOI: 10.5213/inj.2142100.050. View

10.

Kuo H, Chancellor M . Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009; 104(5):657-61. DOI: 10.1111/j.1464-410X.2009.08495.x. View

11.

Lucioni A, Bales G, Lotan T, McGehee D, Cook S, Rapp D . Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008; 101(3):366-70. DOI: 10.1111/j.1464-410X.2007.07312.x. View

12.

Li H, Zhang Z, Peng J, Xin Z, Li M, Yang B . Treatment with low-energy shock wave alleviates pain in an animal model of uroplakin 3A-induced autoimmune interstitial cystitis/painful bladder syndrome. Investig Clin Urol. 2019; 60(5):359-366. PMC: 6722408. DOI: 10.4111/icu.2019.60.5.359. View

13.

Smith C, Gangitano D, Munoz A, Salas N, Boone T, Aoki K . Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int. 2008; 52(6):1068-75. PMC: 2440726. DOI: 10.1016/j.neuint.2007.11.006. View

14.

Gupta P, Gaines N, Sirls L, Peters K . A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care. Transl Androl Urol. 2016; 4(6):611-9. PMC: 4708537. DOI: 10.3978/j.issn.2223-4683.2015.10.10. View

15.

Jhang J, Ho H, Jiang Y, Lee C, Hsu Y, Kuo H . Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. PLoS One. 2018; 13(6):e0198816. PMC: 5991750. DOI: 10.1371/journal.pone.0198816. View

16.

Mussano F, Genova T, Munaron L, Petrillo S, Erovigni F, Carossa S . Cytokine, chemokine, and growth factor profile of platelet-rich plasma. Platelets. 2016; 27(5):467-71. DOI: 10.3109/09537104.2016.1143922. View

17.

Dong M, Yeh F, Tepp W, Dean C, Johnson E, Janz R . SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006; 312(5773):592-6. DOI: 10.1126/science.1123654. View

18.

Ilyasova D, Scarbrough P, Spasojevic I . Urinary biomarkers of oxidative status. Clin Chim Acta. 2012; 413(19-20):1446-53. PMC: 3424057. DOI: 10.1016/j.cca.2012.06.012. View

19.

Yamada T, Nishimura M, Mita H . Increased number of apoptotic endothelial cells in bladder of interstitial cystitis patients. World J Urol. 2007; 25(4):407-13. DOI: 10.1007/s00345-007-0174-7. View

20.

Nickel J, Tripp D . Clinical and psychological parameters associated with pain pattern phenotypes in women with interstitial cystitis/bladder pain syndrome. J Urol. 2014; 193(1):138-44. DOI: 10.1016/j.juro.2014.07.108. View